See more : Axcap Ventures Inc. (GARLF) Income Statement Analysis – Financial Results
Complete financial analysis of NeonMind Biosciences Inc. (NMDBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeonMind Biosciences Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- OFS Credit Company, Inc. (OCCIN) Income Statement Analysis – Financial Results
- SiteOne Landscape Supply, Inc. (SITE) Income Statement Analysis – Financial Results
- Savills plc (SVLPF) Income Statement Analysis – Financial Results
- Qianhe Condiment and Food Co., Ltd. (603027.SS) Income Statement Analysis – Financial Results
- Nitta Corporation (5186.T) Income Statement Analysis – Financial Results
NeonMind Biosciences Inc. (NMDBF)
About NeonMind Biosciences Inc.
NeonMind Biosciences Inc. engages in the discovery, development, and commercialization of medicinal and psychedelic mushrooms for mental illnesses. It is developing psilocybin-based products comprising mushroom-infused products and other mushroom-infused products to treat weight loss and management. The company was formerly known as Flourish Mushroom Labs Inc. and changed its name to NeonMind Biosciences Inc. in April 2020. NeonMind Biosciences Inc. was incorporated in 2019 and is based in Oakville, Canada. NeonMind Biosciences Inc. is a subsidiary of The Yield Growth Corp.
| Metric | 2022 | 2021 | 2020 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 415.80K |
| Cost of Revenue | 0.00 | 0.00 | 250.00 |
| Gross Profit | 0.00 | 0.00 | 415.55K |
| Gross Profit Ratio | 0.00% | 0.00% | 99.94% |
| Research & Development | 149.02K | 1.36M | 269.52K |
| General & Administrative | 1.28M | 4.63M | 1.53M |
| Selling & Marketing | 320.16K | 1.79M | 184.85K |
| SG&A | 1.60M | 6.42M | 1.71M |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.75M | 7.78M | 1.99M |
| Cost & Expenses | 1.75M | 7.78M | 1.99M |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 279.51K | 33.44K | 25.95K |
| Depreciation & Amortization | 1.13K | 689.00 | 4.05K |
| EBITDA | -1.75M | -7.78M | -1.62M |
| EBITDA Ratio | 0.00% | 0.00% | -389.06% |
| Operating Income | -1.75M | -7.78M | -1.62M |
| Operating Income Ratio | 0.00% | 0.00% | -390.03% |
| Total Other Income/Expenses | -282.98K | 1.09M | -1.06M |
| Income Before Tax | -2.03M | -6.68M | -2.68M |
| Income Before Tax Ratio | 0.00% | 0.00% | -643.86% |
| Income Tax Expense | 279.51K | 556.50K | -23.00K |
| Net Income | -2.03M | -7.21M | -2.68M |
| Net Income Ratio | 0.00% | 0.00% | -643.86% |
| EPS | -53.93 | -7.33 | -2.86 |
| EPS Diluted | -53.93 | -7.33 | -2.86 |
| Weighted Avg Shares Out | 37.72K | 983.30K | 936.92K |
| Weighted Avg Shares Out (Dil) | 37.72K | 983.30K | 936.92K |
NeonMind to Present at H.C. Wainwright Bioconnect Conference
VANCOUVER, BC / ACCESSWIRE / January 6, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company, announced today that Robert Tessarolo, President and Chief Executive Officer, will participate in the H.C. Wainwright...
NeonMind to Present at H.C. Wainwright 2nd Annual Psychedelics Virtual Conference
VANCOUVER, BC / ACCESSWIRE / December 2, 2021 / NeonMind Biosciences Inc. (CSE:NEON) (OTCQB:NMDBF) (FRA:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management...
NeonMind to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th
VANCOUVER, BC, Oct. 7, 2021 /PRNewswire/ -- NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) ("NeonMind" or the "Company"), based in Vancouver, focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, today announced that...
NeonMind Advances Strategy for Specialty Clinic Launch
Company expects to launch first specialty clinic locations by early 2022 NeonMind-branded specialty mental health clinics to bring innovative interventional psychiatry treatments to underserved populations in Canada VANCOUVER, BC / ACCESSWIRE / September 28, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FSE:6UF)...
NeonMind Strengthens its Specialty Clinics Advisory Board with Appointment of Mood Disorders and Ketamine Expert Dr. Gustavo Vazquez, MD, PhD.
Company Continues to Expand Its Scientific Expertise with Noted Expert in Utilizing Ketamine for Treatment Resistant Depression VANCOUVER, BC / ACCESSWIRE / September 22, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness...
NeonMind Appoints Ketamine and Neurostimulation Expert Dr. Roumen Milev, MD, PhD to Specialty Clinic Advisory Board
Company Broadens Scientific Expertise with Addition of Mental Health Expert in Setting Up and Managing Interventional Psychiatric Clinics VANCOUVER, BC / ACCESSWIRE / September 16, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FSE:6UF) ("NeonMind'' or the "Company"), an integrated drug development and...
NeonMind Announces Divestiture of Consumer Related and Other Non-Core Assets
Reflects Strategic Focus on Psychedelic Treatments with Major Milestones in 2021 VANCOUVER, BC / ACCESSWIRE / September 13, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind", the "Company"), announced it has completed the sale of assets related to its consumer division,...
NeonMind to Present at H.C. Wainwright 23rd Annual Global Investment Conference
VANCOUVER, BC / ACCESSWIRE / September 8, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FRA:6UF) ("NeonMind''or the "Company"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, today announced...
NeonMind Announces DTC Eligibility
VANCOUVER, BC / ACCESSWIRE / August 25, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FFE:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced...
NeonMind Receives Health Canada Approval for its Functional Mushroom Formulation 'Mindful Blend'
VANCOUVER, BC / ACCESSWIRE / August 17, 2021 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBF)(FFE:6UF) ("NeonMind'' or the "Company"), an integrated drug development and wellness company focused on the potential therapeutic uses of psilocybin for treating obesity and weight management conditions, announced...
Source: https://incomestatements.info
Category: Stock Reports